SecBot SecBot

OCUL drug pipeline

OCULAR THERAPEUTIX, INC · 1 rated drug
$6.01
−3.2% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±5.5%
1-day, median of 2 events
IV rank
No data
No current options data
Rated drugs
1
1 bullish
Phase 3 trials
1
0 with results posted

Upcoming catalysts

1 dated
  1. Jan 8, 2027
    OTX-TKI
    Phase 3 primary completion

Drugs

soonest catalyst first
▲ bullish
Impact
PhasePhase 3 (pivotal completed; NDA submission imminent)
Time to marketIf the NDA is submitted in Q4 2026 as planned, a standard FDA review would take approximately 10 months, suggesting a potential approval decision in late 2027. A priority review (possible under 505(b)(2) pathway) could shorten this to 6-8 months, potentially yielding a mid-2027 decision.

OTX-TKI axitinib intravitreal implant Updated Nov 10

What to watch

Watch for the NDA submission announcement, expected any week given the Q4 2026 timeline confirmed on the November 9 earnings call. After submission, the next catalysts are FDA acceptance (60-day filing review) and PDUFA date assignment. A standard review would set a decision in late 2027; a priority review could accelerate to mid-2027. The stock's wide gap between current price ($6.85) and analyst targets ($25.45 mean) reflects both the binary regulatory risk and the potential for significant upside if the NDA is accepted and reviewed favorably.

Bull case
  • Phase 3 SOL-1 trial met its primary endpoint with superiority over aflibercept 2 mg, a first for any novel investigational therapy in wet AMD
  • FDA alignment secured for NDA submission in Q4 2026 under 505(b)(2) pathway, potentially enabling accelerated review
  • Strong analyst consensus: 18 Buy/Strong Buy ratings, 1 Hold, 0 Sell; mean price target of $25.45 implies ~272% upside from $6.85
Bear case
  • Stock has fallen sharply from its 52-week high of $16.44 to $6.85, indicating the market is pricing in significant execution or commercial risk
  • Elevated short-sale volume (z-score 2.02 vs own history) and multiple insider sales (CEO Dugel sold at $10.77, other officers sold in Oct-Nov 2026) suggest skepticism
  • DEXTENZA revenue is modest (~$12.9M in Q3 2026) and missed analyst estimates, while R&D spending jumped to $74.8M, widening net losses

Other drugs in filings and trials

no drug report yet
  • DEXTENZA Last: Approval · Nov 30, 2018

Past FDA events & how the stock moved

2 events
DateDrugEvent1 day5 days
Jun 17, 2026OTX-TKINDA filed+5.5%+9.2%
Nov 30, 2018DEXTENZAApproval−5.5%−4.0%

Clinical trials

2 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
OTX-TKIStudy to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular DegenerationPhase 3Active not recruiting825Jan 8, 2027
OTX-TIC low dose Travoprost Intracameral ImplantA Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)Phase 2Completed · results83Jan 24, 2024